AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference
Lausanne, Switzerland, November 23, 2022 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced the upcoming presentations of its vaccine technology SupraAntigen®, and of its anti-Tau and anti-Abeta investigational candidates, at the 15th Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Francisco, California (United States) and online, on November 29 – December 2, 2022.
During the conference, Prof. Johannes Streffer, AC Immune’s Chief Medical Officer, will present interim data from the anti-phospho-Tau vaccine program currently in a Phase 1b/2a study. Dr. Marie Kosco-Vilbois, Chief Scientific Officer, will detail the Company’s proprietary SupraAntigen® technology platform, enabling liposome-based generation of conformation-specific antibodies and active immunotherapies.
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “These CTAD presentations showcase our experienced team’s ability to discover and develop targeted novel active vaccines using our SupraAntigen®-V technology platform. SupraAntigen® vaccines have been shown in clinical testing to be safe and generate broad polyclonal antibody responses highly specific for different neurotoxic protein species in Alzheimer’s, Parkinson’s and other neurodegenerative diseases. This is exemplified by the polyclonal response induced by ACI-24.060, featuring antibodies that preferentially bind to clinically validated toxic Abeta species, oligomers and pyroglutamate Abeta, established hallmarks of AD progression. We look forward to presenting at CTAD new data from our SupraAntigen® anti-pTau vaccine ACI-35.030, highlighting its safety, tolerability and immunogenicity profile.”
In addition, there will be presentations on fluid biomarkers covering partnered programs for the Phase 2 crenezumab anti-Abeta antibody and Phase 2 semorinemab anti-Tau antibody, both partnered with Genentech, a member of the Roche group; as well as data from Tau-positron emission tomography (PET) tracer diagnostic candidate PI-2620, partnered with Life Molecular Imaging (LMI).
About AC Immune SA
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU and SG. Morphomer® is a registered trademark of AC Immune SA in CN, CH, GB, JP, KR, NO and RU.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
Forward looking statements
The "Who, What, and How" of IoT: Why Developing an IoT Solution Takes an Ecosystem - Selecting the Right Integration Partner
Registration Counters Open
Special Presentation by Sangoma